This article reviews our 10 years of clinical experience in performing rotary gamma knife in patients with secretory pituitary MI-503 solubility dmso adenomas. The focus of this research is to define accurately the efficacy, safety, complications, and role of rotary gamma knife for treatment of secretory pituitary adenomas. Methods Characteristic of the patients Between 1997 and 2007, 1681 patients with a diagnosis

of secretory pituitary adenoma were treated with MASEP rotary gamma knife(MASEP instruments, Inc., Shenzhen, P.R. China) in our medical center. The patients with secretory pituitary adenoma treated in our studies are those loss convenience, intolerant of or resistant to medical therapies. Some of them were evaluated Nutlin-3 ic50 ineligible for neurosurgery www.selleckchem.com/products/Roscovitine.html because of body health and the others rejected to surgery on private choice or economic condition. 347 patients under medical therapies irregularly less than 3 months after

MASEP GKRS and getting follow-up with at least 60 months were taken in our study, and those with follow-up less than 60 months or taken medical therapies regularly after MASEP GKRS were excluded. Our study population comprised 162 men (46.7%) and 185 women (53.3%). Their age ranged from 17 to 86 years (mean 41.8). The patients presented with a 1- to 19-year history (mean 2.7). In 47 of these patients some form of prior treatment such as transsphenoidal resection, or craniotomy and resection had been conducted. The others were deemed ineligible for microsurgery because of body health or private choice, and MASEP GKRS served as the primary treatment modality. Endocrinological, ophthalmological, and neuroradiological exams were taken for all of them. The diagnosis was made on the basis of magnetic resonance imaging (MRI) findings, endocrinological exam findings, pathological findings (available for postoperative patients), and their clinic history. Of these patients treated, not 68(19.6%) had a diagnosis of adrenocorticotropic hormone-secreting adenomas, 176(50.7%) had a diagnosis of prolactinomas, and 103(29.7%) had growth hormone-secreting adenomas. The mean follow-up period

was 67.3 months (range 60~90 months) (Table 1). Table 1 Characteristics of patients with pituitary adenomas treated with MASEP GKRS Characteristic Value(%) The statistics of the population      Sex   male 162(46.7) female 185(53.3)    Mean age(yrs) 41.8 (range17~86)    Mean history(yrs) 2.7(range1 to 19) No. of previous treatments   transsphenoidal resection 27* craniotomy and resection 23 Mean follow-up after GKRS(mos) 67.3 (range 60~90) Type of adenomas      ACTH adenomas 68(19.6) microadenoma(size, cm3) 21 (0.8~1.1) macroadenoma(size, cm3) 47 (1.2~6.4)    Prolactinomas 176(50.7) microadenoma(size, cm3) 0 macroadenoma(size, cm3) 176(1.2~17.9)    GH adenomas 103(29.7) microadenoma(size, cm3) 0 macroadenoma(size, cm3) 103(2.3~21.